Treatment Patterns and Characteristics of Patients Prescribed Opdivo Qvantig

NCT07636863 · clinicaltrials.gov ↗

COMPLETED

Status

200

Enrollment

INDUSTRY

Sponsor class

Conditions

Cancer

Interventions

DRUG: Nivolumab
COMBINATION_PRODUCT: Subcutaneous nivolumab combined with hyaluronidase

Sponsor

Bristol-Myers Squibb